These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29765782)

  • 1. Biosimilars Have Arrived: Rituximab.
    Greenwald M; Tesser J; Sewell KL
    Arthritis; 2018; 2018():3762864. PubMed ID: 29765782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical guide about biosimilar data for health care providers treating inflammatory diseases.
    Markenson J; Alvarez DF; Jacobs I; Kirchhoff C
    Biologics; 2017; 11():13-21. PubMed ID: 28280299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
    Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
    Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars-Emerging Role in Nephrology.
    Wish JB
    Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.
    Subramanian J; Cavenagh J; Desai B; Jacobs I
    Cancer Manag Res; 2017; 9():131-140. PubMed ID: 28479860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
    Monk BJ; Huh WK; Rosenberg JA; Jacobs I
    Gynecol Oncol Res Pract; 2017; 4():7. PubMed ID: 28344818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical Primer on Biosimilar Clinical Development.
    Isakov L; Jin B; Jacobs IA
    Am J Ther; 2016; 23(6):e1903-e1910. PubMed ID: 26766293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars and the extrapolation of indications for inflammatory conditions.
    Tesser JR; Furst DE; Jacobs I
    Biologics; 2017; 11():5-11. PubMed ID: 28255229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
    Carrascosa JM; Jacobs I; Petersel D; Strohal R
    Dermatol Ther (Heidelb); 2018 Jun; 8(2):173-194. PubMed ID: 29549597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.